BATS:BLUE   bluebird bio, Inc.

Asymmetric upside here on a biotech stock that's been absolutely battered. Runway for pharmaceutical approvals are ripe and Dec 20 could launch this.


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.